SEMA7A and head and neck squamous cell carcinoma: Finally, targeting SEMA7A glycosylation enhanced the sensitivity of HNSCC cells to EGFR-targeted therapy, CD8+ T-cell-mediated immunotherapy and DOX-induced ICD.